孔德胜赵红丽董敏孙国勋施婺丹洪珞珈△.雷利度胺治疗难治复发急性粒细胞白血病临床观察[J].,2012,12(23):4493-4495 |
雷利度胺治疗难治复发急性粒细胞白血病临床观察 |
Clinical Observation of Lenalidomide Treat Relapsed or Refractory AcuteMyeloblastic Leukemia |
|
DOI: |
中文关键词: 雷利度胺;难治复发 急性粒细胞白血病;治疗 |
英文关键词: Lenalidomide Relapsed or Refractory Acute Myeloblastic Leukemia Treat |
基金项目:黑龙江省留学人员归国基金(LC08C24) |
|
摘要点击次数: 887 |
全文下载次数: 1127 |
中文摘要: |
目的:观察雷利度胺治疗难治复发急性粒细胞白血病的疗效及不良反应。方法:给予雷利度胺单药治疗,雷利度胺50mg/d,
口服给药,连续给药21 天,28 天为一个疗程。结果:应用雷利度胺4(2~6)个疗程,5 例有效,2 例获得完全缓解,2 例部分缓解,
1 例因疾病迅速进展死亡退出试验。不良反应主要为疲乏4 例,中性粒细胞减少性发热3 例,中粒细胞减少4 例,血小板减少1
例,贫血1 例。结论:应用雷利度胺治疗难治复发白血病有效,不良反应轻微且易于耐受。 |
英文摘要: |
Objective: To observe toxicities and efficacy in patients relapsed or refractory acute myeloblastic leukemia with
lenalidomide. Methods: Lenalidomide was given orally at doses of 50mg daily on days 1 through 21 of 28-day cycles. Results: Six
Patients were given a median of four prior therapies (range, two to six therapies), five patients with AML responded. Two of 6 patients
achieved complete remission (CR), two of 6 patients achieved partial remission (PR), one of 6 patients achieved Peripheral blood
improvement,One patient had disease progression death. Toxicities of lenalidomide were Fatigue (4/6), febrile neutropenia (3/6),
neutropenia (4/6), thrombocytopenia(1/6), anemia(1/6). Conclusions: Lenalidomide has significant activity in relapsed or refractory acute
myeloblastic leukemia patients and the toxicities was active with relatively low toxicity in patients with relapsed/refractory AML. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |